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ABSTRACT 
Introduction: There is conflicting evidence on the impact of atrial fibrillation (AF) type, i.e. 
non-paroxysmal (NPAF) or paroxysmal (PAF), on thromboembolic recurrence. The consensus 
of risk equivalence is greatly based on historical evidence, focusing on initial stroke risks. We 
conducted a systematic review and meta-analysis to describe the impact of AF type on the risk 
of thromboembolic recurrence, mortality and major haemorrhage in patients with previous 
stroke. 
 
Methods: We systematically searched four multidisciplinary databases from inception to 
December 2018. We selected observational studies investigating clinical outcomes in patients 
with ischaemic stroke and AF, stratified by AF type. We assessed all included studies for risk 
of bias using the ‘Risk of Bias In Non-randomised Studies – of Exposures’ tool. The 
Comprehensive Meta-Analysis Software was used to calculate odds ratios (OR) from crude 
event rates. 
 
Results: After reviewing 14,127 citations, we selected 108 studies for full-text screening. We 
extracted data from 26 studies, 23,054 patients. Overall, risk of bias was moderate. The annual 
incidence rates of thromboembolism in patients with NPAF and PAF were 7.1% (95%CI: 4.2-
11.7)% and 5.2% (95%CI: 3.2-8.2)%, respectively. The OR for thromboembolism in patients 
with NPAF versus PAF was 1.47 (95%CI: 1.08-1.99, p=0.013). The annual mortality rates in 
patients with NPAF and PAF were 20.0% (95%CI: 13.2-28.0)% and 10.1% (95%CI: 5.4-
17.3)% respectively, OR=1.90 (95% CI: 1.43-2.52, p< 0.001). There was no difference in rates 
of major haemorrhage, OR=1.01 (95%CI: 0.61-1.69, p=0.966). 
 
Conclusion: In patients with prior stroke, NPAF is associated with significantly higher risk of 
thromboembolic recurrence and mortality than PAF. Although current guidelines make no 
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distinction between NPAF and PAF for secondary stroke prevention, future guidance and risk 
stratification tools may need to consider this differential risk. (PROSPERO ID: 
CRD42019118531)  
Page 5 of 36 
 
INTRODUCTION 
Atrial fibrillation (AF) is an atrial arrhythmia characterised by uncontrolled, rapid firing of 
atrial action potentials. This causes reduced cardiac output and turbulent flow, which can lead 
to blood coagulation and emboli.1 Hence, AF is associated with an increased risk of stroke and 
consequently death.2 AF is sub-classified into paroxysmal (PAF) and non-paroxysmal (NPAF) 
forms. PAF refers to short spontaneously terminating episodes, while NPAF is persistent or 
permanent. PAF, NPAF and sinus rhythm are often difficult to differentiate and are recognised 
as non-mutually exclusive categories. Diagnoses differentiating PAF and NPAF are limited by 
the ability of current monitoring detection algorithms and arbitrary cut offs of AF burden. 
Emerging evidence suggests that even in the absence of clinical AF, atrial cardiopathy may 
associated with thromboembolism, thus determining cardiac thrombogenicity remains more 
complex than categorisation of AF burden.3 Nevertheless, guidelines suggest that 
categorisation of AF burden remains practical. The risk of stroke in AF patients is considered 
independent of AF type. Stroke-risk stratification scores that inform prescribing and 
management, are based on sex, age and comorbidities rather than AF type.4 This consensus of 
relative risk equivalence in patients with PAF and NPAF is based on historical evidence 
evaluating the risk of index stroke.5 Despite some conflicting evidence 6-8, the European 
Society of Cardiology (ESC) guidelines do not recommend that AF type should be a major 
factor in making decisions regarding oral anticoagulation (OAC) therapy.9 However, due to 
limited studies, the impact of AF type on outcomes following acute stroke remains unclear.  
 
Although previous systematic review has examined the role of AF type as a risk factor for 
initial stroke occurrence and adverse outcomes,6 no systematic review has investigated the role 
of AF type following acute ischaemic stroke, i.e. as a risk factor for thromboembolic 
recurrence, mortality and major haemorrhage. The risk of ischaemic stroke is significantly 
higher in AF patients who have had a previous stroke than those who have not.10 Due to higher 
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event rates, the impact of AF type on secondary prevention outcomes may be more 
pronounced.  
 
Decisions to start effective AF-related stroke thrombo-prophylaxis following acute ischaemic 
stroke or intracerebral haemorrhage are rarely clear cut: patients have reluctance and own 
prejudices, relative contraindications, and are influenced by their individual clinicians’ 
perceptions of risks and benefits. In addition, the current AF risk stratification tools are not 
perfect. A better understanding of risk factors could improve their prognostic and clinical 
utility. There are plausible reasons to think that AF type may be an important factor that has 
hitherto been ignored.   
 
We conducted a systematic literature review and meta-analysis of observational studies to 
evaluate the impact of atrial fibrillation type on the risk of thromboembolic recurrence (stroke 
and systemic embolism), major haemorrhage and mortality in patients with prior stroke.  
 
 
METHODS 
Inclusion and exclusion criteria 
We conducted a systematic literature search of multidisciplinary databases: MEDLINE 
(OVID), EMBASE (OVID), Web of Science (Thomson Reuters), CINAHL (EBSCO) to 
identify observational studies in which clinical outcome data were prospectively or 
retrospectively collected from inception to December 2018. We registered the study protocol 
on PROSPERO (CRD42019118531). 
 
Study designs 
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We included prospective and retrospective cohort studies and case series that investigated 
patients with AF post-stroke and distinguished between AF types. We did not include studies 
on topics other than stroke outcomes in AF patients, unless stroke outcomes were reported. 
We excluded randomised control trials, as they are not representative of natural population 
frequencies. We also excluded review articles, commentaries, conference papers and case 
reports. We placed no restrictions on the basis of language; however, any foreign-language 
studies identified were only included when they could be translated into English.  
 
Patients/Participants 
We included studies in which patients had an ischaemic stroke/ transient ischaemic attack 
(TIA) of any form consistent with the current (ICD-10) World Health Organisation (WHO)10 
definition, diagnosed in a hospital setting. We included mixed population studies (i.e. studies 
including patients with index and recurrent stroke) if they differentiated between AF types. 
We contacted the studies’ authors of mixed population studies if: 1) the data of interest were 
not available from the original report, 2) they had been conducted within the last 10 years, and 
3) they differentiated between AF types. We allowed one month for the authors to reply, with 
a follow-up/ reminder email after two weeks. We included studies of authors who provided us 
with outcome data of interest within the specified time frame.  
 
Exposures 
We included studies if their definition of AF was compatible with the current International 
Classification of Disease (ICD-10)10. The definitions of AF types in included studies had to be 
consistent with current American Heart Association (AHA), American College of Cardiology, 
European Society of Cardiology (ESC) and Heart Rhythm Society (HRS) guideline 
classifications of AF patterns:  
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1. Paroxysmal AF (PAF): Self-terminating, typically within 48 hours, but may continue 
up to 7 days. An AF episode terminated by cardioversion may still be considered 
paroxysmal if this (i.e. cardioversion) occurs within 7 days. 
2. Non-paroxysmal AF (NPAF): 
a. Persistent AF: AF that lasts longer than 7 days, including episodes terminated 
by cardioversion after 7 or more days. 
b. Long-standing persistent AF: Continuous AF lasting for at least a year until a 
rhythm control strategy is adopted.  
c. Permanent AF: AF that is accepted by patient and physician, therefore not 
including patients on rhythm control therapy.9, 11, 12  
 
We included studies that failed to use the current terminology of paroxysmal and non-
paroxysmal AF if their definitions were considered compatible, as judged by consensus of two 
authors (AM, AHAR). We grouped the terms ‘sustained’, ‘constant’ or ‘chronic’ AF as NPAF 
and ‘intermittent’ or ‘recurrent’ AF as PAF. We excluded studies failing to differentiate 
between AF types.  
 
Outcomes 
Our outcomes of interest were the incidence of stroke and systemic embolism, major 
haemorrhage and mortality: 
1. Ischaemic stroke or systemic embolism diagnosed as per definition taken from the 
original article. This includes stroke recurrence during the treatment period and during 
follow-up, which was either definitely ischaemic (haemorrhage excluded by brain 
imaging or autopsy), or of unknown type (no brain imaging or autopsy performed); 
2. Death from any cause during the scheduled follow-up period 
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3. Any intracerebral or major extracranial haemorrhage during the scheduled treatment 
period: 
a. Intracerebral haemorrhage, including symptomatic haemorrhagic 
transformation of the cerebral infarct, during the scheduled treatment period 
and during follow-up. The haemorrhage must have been confirmed by 
appropriate brain imaging after clinical deterioration or by autopsy  
b. The definition of major haemorrhage was taken from the original article but if 
none was given it was defined as any fatal bleed, or bleeding severe enough to 
require transfusion or operation.  
 
We included studies, in which these outcomes for patients with a previous, definitely 
ischaemic stroke were extractable (i.e. stroke population and mixed population studies).  
 
Study selection 
The search syntax for MEDLINE was created in cooperation with a research librarian of the 
University of Glasgow. We adapted this search strategy for the other databases 
(Supplementary Table 1). All databases were accessed on the 18th of December 2018. We 
reviewed titles and abstracts using Covidence software (version 1.0, Veritas Health 
Innovation, Australia). We used the reference lists of retrieved articles for hand searches to 
identify additional relevant studies. As our emphasis was on published, peer-reviewed articles, 
we did not search grey literature beyond the scope of the included search engines and hand 
searches.  
 
Data extraction and statistical analysis 
Risk of Bias Assessment  
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All included studies underwent risk of bias assessment (Supplementary Table 2). We used the 
ROBINS-E (Risk of Bias In Non-randomised Studies – of Exposures) tool for non-randomised 
control trials.13 We judged all studies, with a particular emphasis on the focus of the paper, 
selection bias (i.e. recruitment method and exclusion and inclusion criteria), classification of 
AF and the acknowledgement of confounding factors and co-exposures. Any studies with 
serious risk of bias were excluded in sensitivity analyses.  
 
Data extraction 
We extracted the total number of patients with PAF and NPAF who had a previous ischaemic 
stroke, along with any data on the incidence of recurrent thromboembolic events, mortality 
and major haemorrhage. We converted Kaplan-Meier curves and risk ratios into crude event 
numbers to allow data uniformity. We also recorded follow-up period and OAC data. We 
stored all data on an electronic spreadsheet (Excel, version 2016 Microsoft, USA) after 
extraction.  
 
Statistical analysis 
The primary outcome of the meta-analyses was the incidence of recurrent thromboembolic 
events. The secondary outcomes were incidence of all-cause mortality and major 
haemorrhage. These analyses were conducted using Comprehensive Meta-Analysis software 
version 3 (Biostat, USA). As specified in the study protocol, we created a random-effects 
model to generate a pooled estimate of the summary event rates for both, PAF and NPAF and 
performed a subgroup analysis accounting for OAC use post-stroke. The a-priori decision to 
use a random-effects model was made to accommodate the anticipated variation in study 
design and small sample size of observational studies. We calculated annual event rates by 
dividing the total number of events by length of follow up (in years). Our analysis assumes 
that the incidence of events was constant over time. We assessed heterogeneity among studies 
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by visual inspection of forest plots and 𝐼2. We also calculated odds ratios (OR) for the 
outcomes to compare NPAF and PAF event rates. This analysis only included studies that 
reported on both AF types. We assessed the strength of the summary data post stroke 
comparing different AF types using the GRADE criteria14  (Supplementary Table 3). We 
visually inspected the funnel plots of outcomes for publication bias.  
 
 
RESULTS 
We retrieved 14,127 references. Following deduplication, we screened 10,855 references. 
Finally, we included 108 studies, of which 23 had the data of interest available from the 
original report. We contacted authors of the remaining 93 studies and received data from 3 
further studies. Therefore, we extracted data from a total of 26 studies, reporting outcomes on 
23,054 patients.15-40 Figure 1 shows the process of study selection.  
[insert Figure 1.] 
 
 
Page 12 of 36 
 
Table 1: Baseline characteristics of all included non-randomised observational studies 
Author 
name and 
date 
Study type Number of 
patients in 
study with 
history of 
previous 
stroke 
Number of 
patients by 
AF type 
 
Inclusion 
criteria 
Comparators/ 
Exposure 
Oral 
anticoagulation 
during follow-up 
(%) 
Follow-up 
(mean or 
median) 
PAF NPAF PAF NPAF 
Al-Khalili 
2016 15 
Retrospective 
cohort study 
766 61 24 AF patients in 
Stockholm 
health centre 
treated with 
NOACs 
Dabigatran versus 
Rivaroxaban 
versus Apixaban 
100% 100% 395 days 
Aronow 
1999 16 
Prospective 
cohort study 
136 - 136 Chronic AF 
patients ages 
62 years or 
older 
Warfarin versus 
Aspirin 
- 50%*  3 years 
Azoulay 2012 
17 
Retrospective 
cohort study 
with case-
control 
analysis 
4643 - 4643 Chronic AF 
patients in the 
UK General 
Practice 
Research 
Database† 
Warfarin versus 
Aspirin  
- 23% 3.9 years 
Baturova 
2017 18 
Prospective 
cohort study 
336 65 44 AF patients 
who suffered 
first-ever 
ischaemic 
stroke in the 
Lund Stroke 
Register 
Effect of heart 
rhythm and OAC 
use  
45% 45%* 10 years 
Britton 1984 
19 
Prospective 
cohort study 
288 31 61 AF patients 
diagnosed 
with brain 
AF versus sinus 
rhythm  
- - 10 days 
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infarction in 
Stockholm  
Christensen  
2014 20 
Prospective 
cohort study 
85 18 - Patients with 
prior 
cerebrovascul
ar ischaemic 
event without 
prior AF 
diagnosis 
Benefits of PAF 
detection by 
implantable loop 
recorder, no direct 
comparator  
94% - 1.5 years 
Friberg 2010 
21 
Prospective 
cohort study 
298 91 207 Patients with 
AF treated as 
inpatients in 
2002 in 
Stockholm 
AF type 
(paroxysmal 
versus permanent) 
32% 38% 3.6 years 
Grond 2013 
22 
Prospective 
multicentre 
cohort study 
1135 49 - Survivors of 
stroke or 
transient 
ischaemic 
attack (TIA) 
without 
known AF  
Detection rates of 
PAF by 24-hour 
vs. 72-hour holter 
ECG monitoring 
- - Hospital stay 
Koga 2016 
23 
Prospective 
multicentre 
cohort study 
1192 434 758 NVAF 
patients with 
acute 
ischaemic 
stroke or TIA  
Type of AF 
(paroxysmal 
versus sustained) 
-  - 1.8 years 
Levy 1999 24 Prospective 
cohort study 
15 1 14 Patients 
diagnosed 
with AF, none 
hospitalised 
AF type 
(paroxysmal, 
chronic or 
persistent) 
26% 52% 8.6 months 
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Liantinioti 
2017 25 
Single-centre 
prospective 
cohort study 
184 23 - Cryptogenic 
stroke patients 
with no prior 
history of AF  
Duration of PAF  85% - 3 months 
Marini 2005 
26 
Prospective 
cohort study 
3530 55 814 Patients with 
index 
ischaemic 
stroke 
AF versus sinus 
rhythm 
- - 3.75 years 
Ntaios 2013 
27 
Prospective 
cohort study 
811 277 534 AF patients 
with acute 
ischaemic 
stroke 
AF types 
(paroxysmal, 
persistent and 
permanent) 
33.9% 38.8% 10 years 
Önundarson 
1987 28 
Prospective 
cohort study 
6 - 6 Men and 
women of 
Reykjavik  
Chronic AF versus 
sinus rhythm 
- - unclear 
Paciaroni 
2018 29 
Prospective 
cohort study 
2040 886 1154 Patients with 
acute 
ischaemic 
stroke and AF 
PAF versus 
sustained AF  
87.3% 80% 120 days 
Palomäki 
2017 30 
Retrospective 
cohort study 
3256 1448 1808 AF patients 
with acute 
ischaemic 
stroke or TIA 
PAF versus 
chronic AF  
32.2% 63.6% 30 days 
Petty 1998 31 Retrospective 
cohort study 
1111 129 138 All residents 
of Rochester 
who have 
suffered from 
stroke 
Characteristics 
that could impact 
survival and 
recurrence post 
stroke 
- - unclear 
Rietbrock 
2008 32 
Retrospective 
population-
based cohort 
study 
7628 - 7628 Chronic AF 
patients over 
40 years in the 
UK General 
CHADS2 risk 
stratification 
points 
- - 3.3 years 
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Practice 
Research 
Database† 
Staszewski 
2009 33 
Prospective 
cohort study 
178 70 108 AF patients 
with acute 
ischaemic 
stroke and at 
least 72-hours 
of continuous 
ECG 
monitoring 
AF type 
(paroxysmal 
versus permanent) 
- - 6 months 
Tanaka 2016 
34 
Retrospective 
cohort study  
449 178 271 Patients with 
acute 
ischaemic 
stroke and AF 
Age (aged 80 
years or older 
versus younger 
than 80) 
- - 90 days 
Tsivgoulis 
2005 35 
Prospective 
cohort study 
207 66 141 AF patients 
with first-ever 
ischaemic 
stroke 
Oral 
anticoagulants 
versus aspirin 
- - 7.4 years 
Wolf 1978 36 Prospective 
cohort study 
20 - 20 Men and 
women of 
Framingham 
aged 30 to 62 
Chronic AF versus 
sinus rhythm 
- - unclear 
Yamanouchi 
1988 37 
Retrospective 
cohort study 
23 5 18 NVAF 
patients with 
sustained 
embolic brain 
infarction on 
warfarin 
anticoagulatio
n treatment 
Warfarin versus no 
treatment (autopsy 
series)‡ 
 
100% 100% 3.8 years 
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Yanagisawa 
2016 38 
Prospective 
cohort study 
64 27 37 Elderly 
patients with 
AF receiving 
outpatient 
treatment in 
Nagoya 
Body mass index - - 1.6 years 
Yu 2018 39 Retrospective 
cohort study 
69 - 69 NV, persistent 
AF patients 
who survived 
hospital stay  
Type of anti-
thrombotic 
treatment 
- 41.1% 360 days 
Zolotovskay
a 2018 40 
Prospective 
cohort study 
661 153 354 NVAF 
patients with 
history of 
carotid cardio-
embolic 
stroke without 
carotid artery 
stenosis 
Type of AF (first 
diagnosed, 
paroxysmal, 
persistent and 
constant) 
- - 1 year 
*subgroup analysis of OAC versus no OAC treatment available from original report 
†Same data-base used, therefore data was not taken from these studies for the same outcomes 
‡autopsy series was not included in meta-analysis 
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Table 1 presents the baseline characteristics of included studies.  
 
Notably, two studies (Azoulay 2012 and Rietbrock 2008)17, 32 were based on a single database 
(UK General Practice Research Database), reporting on thromboembolic recurrence in patients 
from 1993-2008 and 1987-2007, respectively. Thus, to prevent reporting-bias, we used 
Rietbrock 2008 for the analysis of thromboembolic recurrence, due to its larger sample size. 
We extracted major haemorrhage rates from Azoulay 2012, as these data were not available 
from Rietbrock 2008.17, 32 
 
Quality of Evidence 
The risk of bias was assessed for all included studies (Supplementary Table 2). All studies 
were from representative AF populations. Confounding factors were common potential 
sources of bias. Eight studies did not report baseline characteristics stratified by AF types. 
Three studies had significantly older patients or higher incidences of comorbidities in the 
NPAF group, particularly coronary artery disease, hypertension, chronic heart failure, and 
diabetes mellitus. Selection bias was common: 13 studies excluded patients who had died after 
their index stroke. We classified the risk of bias in Petty 1998 31 for reporting outcomes as 
serious, because the relative risk (RR) for all-cause mortality could not be reconciled with 
crude event rates and must have been misreported. We therefore excluded the all-cause 
mortality data from Petty 1998 31 in our analysis.  Follow-up duration was adequate for most 
studies. However, Grond 2013 22 only followed up patients with PAF for the length of hospital 
stay post-stroke, potentially leading to an underestimate of outcome incidences in PAF. The 
funnel plot for the log OR of thromboembolic recurrence indicated potential publication bias 
(Supplementary Figure 1). The distribution of studies was asymmetrical, smaller studies 
tended to show lower OR than larger studies. Visual inspection of the other funnel plots 
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showed greater symmetry. Overall, certainty of evidence, in accordance with the GRADE 
criteria 14, was low (Supplementary Table 3). However, we were conservative in scoring, 
downgrading the evidence for being observational.  
 
The impact of AF type on the recurrence of thromboembolism  
Thromboembolic data were recorded by 18 studies, reporting on a total of 17,627 patients 
(Figure 2). Confounding factors were reported in 10 studies, accounting for 2,535 patients. 
Patients with NPAF had a higher median NIHSS as well as higher rates of ischaemic heart 
disease and congestive heart failure than patients with PAF. The mean reported age was 75 in 
patients with PAF and 77 in patients with NPAF  (Supplementary Table 4). Twelve studies 
compared PAF and NPAF patients and 6 studies reported only on either PAF or NPAF. Three 
studies (Koga 2016, Paciaroni 2018, Tsivgoulis 2005) 23, 29, 35 reported a composite outcome of 
systemic embolism and ischaemic stroke recurrence, whilst the others reported ischaemic 
stroke recurrence alone. The pooled random effects estimates for the risk of recurrent 
thromboembolism in NPAF and PAF patients were 14.1% (95% confidence interval (CI): 
8.2% to 23.1%, Figure 2A) and 9.0% (95% confidence interval: 5.4% to 14.6%, Figure 2B), 
respectively. The average follow-up times of studies reporting thromboembolic recurrence in 
NPAF and PAF were 721 days and 577 days, respectively. We conducted a meta-regression to 
address the assumption of stable risk of thromboembolic recurrence over the follow-up period. 
This showed a slight reduction of risk with increasing follow-up, but of small magnitude. 
(Supplementary Figure 2)  Considering only the studies that reported follow-up duration, the 
average annual event rates of thromboembolic recurrence in NPAF and PAF were 7.1% 
(95%CI: 4.2% to 11.7%) and 5.2% (95%CI: 3.2% to 8.2%), respectively. We performed a 
sensitivity analysis as Aronow 199916 appeared as an outlier. This resulted in a reduction of 
the estimated NPAF annual event rate, 6.4% (95%CI: 4.2% to 9.5%). Direct comparison of 
thromboembolic recurrence in NPAF versus PAF showed significant difference, OR was 1.47 
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(95%CI: 1.08 to 1.99, p=0.013), Figure 2C) based on 12 studies (n= 5,680). Heterogeneity as 
measured with I2 was moderate at 40.1%. The funnel plot indicated potential publication bias 
(Supplementary Figure 1).  
[insert Figure 2.] 
 
Oral anticoagulation 
Subgroup analysis comparing the incidence of thromboembolism in studies with a low 
proportion of patients on OAC (i.e. <50%) to studies with a high proportion of patients on 
OAC (i.e. >50%), showed no significant difference between NPAF and PAF (Supplementary 
Figure 3). The event rate estimates in NPAF and PAF were non-significantly higher in the 
studies reporting lower OAC use, by 3.3% (95%CI: -16.8% to 21.2%) and 3.1% (95%CI: -
14.3% to 25.7%), respectively. 
 
The impact of AF type on all-cause mortality post stroke 
All-cause mortality was reported in 18 studies, representing 7,928 patients. Confounding 
factors were reported in 12 studies, accounting for 5,897 patients.  Patients with NPAF had 
higher median NIHSS and higher rates of ischaemic heart disease and congestive heart failure 
than patients with PAF. The mean reported age was 75 in patients with PAF and 79 in patients 
with NPAF (Supplementary Table 4). Fourteen studies compared NPAF and PAF, and 4 
studies reported on one AF type (Figure 3). The pooled random effects estimates for all-cause 
mortality rate in NPAF and PAF were 34.5% (95%CI: 22.7% to 48.4%, Figure 3A) and 16.3% 
(95%CI: 8.8% to 28.1%, Figure 3B), respectively. The average follow-up times of studies 
reporting all-cause mortality in NPAF and PAF were 630 days and 584 days, respectively. We 
conducted a meta-regression to address the assumption of stable risk of mortality over the 
follow-up period. The risk of mortality in the included studies showed no association to the 
length of follow-up. Excluding all studies that failed to report follow-up duration, the 
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estimated annual mortality rates in NPAF and PAF were 20.0% (95%CI: 13.2% to 28.0%) and 
10.1% (95%CI: 5.4% to 17.3%), respectively. The OR for all-cause mortality was significant, 
1.90 (95%CI: 1.43 to 2.52, p< 0.001, Figure 3C). Heterogeneity was moderate (I2=63.0%).  
[insert Figure 3.] 
 
Baturova 2017 18 was an outlier. We performed a sensitivity analysis including the 3-year all-
cause mortality data of the study (Supplementary Figure 4). Heterogeneity fell to I2=59.8%, 
with lower event rates and OR (1.75, 95%CI: 1.35 to 2.28). Another outlier, as seen in Figure 
3C, was Levy 1999 24. We performed a sensitivity analysis, however due to the small weight 
of the study (n=15), it had little impact on the OR and did not improve the measure of 
heterogeneity (I2=62.4%).  
 
The impact of AF type on the risk of major haemorrhage post stroke  
Major haemorrhage data were reported in 8 studies, based on 2,072 patients (Figure 4). Three 
studies (Azoulay 2012, Grond 2013 and Staszewski 2009) 17, 22, 33 only reported intracranial 
haemorrhages as major haemorrhage events. The estimated rates of major haemorrhage in 
NPAF and PAF were 6.3% (95%CI: 2.9%-13.1%, Figure 4A) and 4.4% (95%CI: 3.0% to 
6.3%, Figure 4B), respectively. There was no difference in major haemorrhage risk, OR was 
1.01 (95%CI: 0.61 to 1.69, p=0.966, Figure 4C). Heterogeneity was negligible (I2=0.00). 
[insert Figure 4.] 
 
 
DISCUSSION 
The impact of AF type on the risk of the thromboembolic recurrence  
Our analysis suggests that, in patients with prior stroke, NPAF is associated with a 
significantly higher risk of thromboembolic recurrence than PAF. Our analysis is distinct from 
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previously conducted studies evaluating the impact of AF type on clinical outcomes,5-8 as the 
vast majority of patients evaluated in these had no prior stroke. Our analysis adds to the 
findings of a recent meta-analysis, suggesting that NPAF is associated with a significant 
increase of thromboembolic risk in patients without prior stroke.6 
 
AF is associated with a six-fold increase in stroke.1 Patients with previous ischaemic stroke 
have an even higher risk. There are several stroke risk-stratification scores for AF patients that 
determine whether OAC therapy is suitable. However, none account for AF type, and current 
guidelines recommend that AF type should not influence decisions regarding OAC therapy.9 
Our analysis challenges this, and indicates that the current belief in the equivalence of 
thromboembolic risk in NPAF and PAF needs to be re-evaluated.  
 
The potential causes for an increased observed thromboembolic recurrence risk in NPAF than 
PAF patients may be burden of AF, inherent differences in pathophysiology and development 
of AF or confounding factors. Even though confounding factors stratified by AF type and 
history of stroke were only reported in 10 studies, these suggest higher rates of comorbidities 
in patients with NPAF and are likely to have contributed to the perceived higher 
thromboembolic risks. Exploring the burden of AF among PAF patients may provide further 
insight into the causes of the differential risk.  
 
Furthermore, AF is a progressive disease. Up to 15% of new-onset PAF patients may progress 
to NPAF within 1 year.41 A previous observational study reported that the progression from 
PAF to NPAF was associated with increased adverse events.42  Even though we did not 
specifically look at patients who had progressed, the higher thromboembolic risk for NPAF in 
our analysis suggests that there may be clinical need to monitor or even prevent the 
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progression of PAF to NPAF. The potential of catheter ablation and risk factor modification, 
which slow disease progression,43, 44 needs further investigation.  
 
We found potential publication bias on inspection of the funnel plot of log OR of 
thromboembolic recurrence, which could have led to an overestimation of the increased risk 
associated with NPAF compared to PAF.  
 
The subgroup analysis adjusting for OAC did not suggest any significant difference in 
thromboembolic recurrence rates in patients with NPAF and PAF. Unfortunately, due to small 
sample size and incomplete reporting of OAC use post-stroke, we were unable to analyse the 
efficacy and risks of OAC in NPAF and PAF appropriately. Our findings do not suggest that 
the effectiveness of OAC in reducing thromboembolic recurrence is dependent on AF type. In 
fact, given the smaller bleeding risk profile of direct OAC and the emerging evidence for 
thromboembolic risks in atrial cardiopathies in the absence of AF, more patients may benefit 
from OAC than are currently treated.3  Future studies investigating the effects appropriately 
could provide further guidance for the initiation of thrombo-prophylaxis post-stroke. 
Moreover, according to ESC guidelines,9 all patients included in the study should have 
received OAC unless contraindicated, as CHA2DS2-VASC recommends OAC in patients with 
previous stroke or TIA. OAC prescription was much lower than anticipated, as several studies 
reported that less than 50% of their patient population were receiving OAC. 
 
The impact of AF type on the risk of mortality post stroke 
Our study implies that, in patients with prior stroke, NPAF is associated with an increased risk 
of all-cause death compared to PAF. The higher risk-profile and comorbidities of NPAF 
patients, in particular higher rates of ischaemic heart disease and congestive heart failure, may 
have contributed to a higher mortality rate. The difference in mortality rate in NPAF versus 
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PAF exceeded the difference of thromboembolic recurrence in our study. As the increased 
mortality in AF is primarily attributed to cerebrovascular events,1 the higher mortality rate 
may have masked thromboembolic recurrence in NPAF patients.  
 
Strengths and Limitations  
One major limitation of the current study was the restricted sample size, a result of the small 
number of included studies, poor reporting and missing stratification of data in mixed 
population studies. This led to wide confidence intervals, particularly for estimated event 
rates. Unfortunately, we were unable to account for the limitations of included studies. The 
data available did not allow the analysis of the impact of patients’ risk profiles (i.e. CHA2DS2-
VASC) on the difference in thromboembolic risks. Further studies are needed to explore the 
impact of AF type on the risk of thromboembolic recurrence at different stroke-risk profiles.  
 
We only included observational studies, only determining association not causation. While 
they are non-randomised and result in a higher risk of confounding bias, they represent normal 
population frequencies and are more suitable for meta-analyses in epidemiology than 
randomised control trials. Our study may also be subject to recording bias and error, as 
retrospective studies rely on the adequacy of registry data.  
 
We analysed both retrospective and prospective studies together. Previous analyses have 
demonstrated differences in outcomes between retrospectively and prospectively identified 
patients with AF.45 These differences may have increased heterogeneity of results and 
decreased reliability of the data. Heterogeneity between studies, evaluated by I2 and visual 
inspection of funnel plots, was moderate for the analysis of thromboembolic recurrence and 
mortality. We used a random-effects model to adjust for this, maintaining the robustness of 
results. 
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We used crude event rates, allowing data uniformity. However, reporting on confounding was 
poor; thus, we did not adjust for significant confounders. Nevertheless, CHA2DS2-VASC, 
HAS-BLED, NIHSS scores and risk factors for stroke were recorded when possible 
(Supplementary Table 4). Not adjusting for confounders, such as age, comorbidities and 
structural heart disease may have led to overestimation of event rates in patients with NPAF. 
A secondary analysis using adjusted risk ratios, where available, could reduce confounding 
bias. We did not conduct such an analysis as adjusted risk ratios were only reported in 3 of the 
26 studies.   
 
Selection bias, in particular survivor bias, was common in the included studies, which may 
have diluted true event rates. We included studies that investigated patient outcomes 
immediately after stroke and others who examined stroke survivors. Thus, our data do not 
provide insight into whether the time since index stroke influences the risk of recurrence and 
death. A sensitivity analysis evaluating outcomes in studies with and without survivor bias 
independently could determine if it has an impact on risks of thromboembolic recurrence or 
mortality. However, this analysis would have limited our sample size further. Furthermore, 
due to large variation in follow-up time and missing longitudinal data, we would still be 
unable to investigate temporal trends of event rates. High mortality rates could have masked 
thromboembolic recurrence in both PAF and NPAF, therefore underestimating the risk of 
stroke recurrence. We were unable to adjust for these competing risks in the study-level meta-
analysis.  
 
All included studies evaluated AF at baseline without re-evaluating exposure status during 
follow-up. As PAF can progress into NPAF over time, some patients with PAF may have 
Page 25 of 36 
 
unknowingly progressed to NPAF. This could have led to an underestimate of the effect of 
NPAF.  
 
 
CONCLUSIONS 
In patients with prior stroke, NPAF is associated with significantly higher risks of 
thromboembolic recurrence and mortality, compared to PAF. This suggests potential clinical 
need to monitor or even prevent the progression of AF. Future stratification scores may need 
to include this parameter to better estimate stroke recurrence risks. Nevertheless, atrial 
thrombogenicity remains more complex than the categorisation of AF burden. All Patients 
with previous stroke should receive OAC therapy, and AF burden should not determine 
whether patients would benefit from OAC.  
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FIGURES & FIGURES LEGENDS 
Figure 1: PRISMA for study selection. The final analysis included 26 studies, reporting data 
from 23,054 patients. 
 
 
 
 
 
Page 31 of 36 
 
 
Figure 2: Thromboembolic estimated event rates for non-paroxysmal (NPAF) and paroxysmal 
atrial fibrillation (PAF) patients and the direct comparison by odds ratio of the risk of 
thromboembolic recurrence.  
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Figure 3: All cause mortality estimated event rates for non-paroxysmal (NPAF) and 
paroxysmal atrial fibrillation (PAF) patients and the direct comparison by odds ratio of the risk 
of all-cause mortality. 
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Figure 4: The estimated event rates of major haemorrhage for non-paroxysmal (NPAF) and 
paroxysmal atrial fibrillation (PAF) and the direct comparison by odds ratio of the risk of 
major haemorrhage. 
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